Physician profile
Steven Edwin Eilers
NPI 1306250790
$3,079.91
in general payments reported to CMS, 2019-2025
32 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $245 · 2021: $260 · 2022: $503 · 2023: $21.67 · 2024: $367 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $664.16 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $350.21 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $280.58 | 2019-2025 | |
| Leo Pharma INC. | $166.60 | 2020-2025 | Anzupgo, Adbry |
| Vyne Pharmaceuticals INC. | $122.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.74 | 2024-2025 | Sotyktu |
| Almirall LLC | $117.40 | 2019-2025 | Klisyri |
| Incyte Corporation | $114.18 | 2021-2025 | Opzelura |
| Botanix Sb INC | $112.73 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $98.10 | 2020-2025 | |
| Allergan, INC. | $97.33 | 2019 | |
| Merz North America, INC. | $97.21 | 2019 | |
| Mayne Pharma Commercial LLC | $81.54 | 2019-2020 | |
| Galderma Laboratories, L.P. | $75.05 | 2021-2025 | Aklief |
| Amgen INC. | $73.34 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.23 | 2025 | |
| Ucb, INC. | $69.56 | 2025 | Bimzelx |
| Lilly USA, LLC | $55.67 | 2022-2025 | Ebglyss, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.57 | 2025 | Cabtreo |
| Paratek Pharmaceuticals, INC. | $47.38 | 2021-2025 | Nuzyra |
| Janssen Biotech, INC. | $44.55 | 2024-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $27.42 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.91 | 2025 | Spevigo |
| Lnhc, INC | $17.27 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $16.50 | 2025 | Vyjuvek |
| Arcutis Biotherapeutics, INC. | $15.68 | 2025 | Zoryve |
| Celgene Corporation | $14.74 | 2019 | |
| Nabriva Therapeutics, Plc | $14.54 | 2022 | |
| Dermira, INC. | $14.17 | 2020 | |
| Smith+Nephew, INC. | $11.71 | 2021 | |
| Organogenesis INC. | $11.08 | 2021 | |
| Epi Health, LLC | $6.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eilers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.